Anzeige
Erschienen in:
02.07.2020 | COVID-19 | COVID-19
Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study
Erschienen in: Neurological Sciences | Ausgabe 7/2020
Einloggen, um Zugang zu erhaltenAbstract
We assessed the prevalence and impact of COVID-19 among multiple sclerosis (MS) patients across Europe by leveraging participant data collected as part of the ongoing EU IMI2 RADAR-CNS major programme aimed at finding new ways of monitoring neurological disorders using wearable devices and smartphone technology. In the present study, 399 patients of RADAR-MS have been included (mean age 43.9 years, 60.7% females) with 87/399 patients (21.8%) reporting major symptoms suggestive of COVID-19. A trend for an increased risk of COVID-19 symptoms under alemtuzumab and cladribine treatments in comparison to injectables was observed. Remote monitoring technologies may support health authorities in monitoring and containing the ongoing pandemic.